Opinion|Videos|September 9, 2024
Strategies for Prevention and Screening of CRM Conditions
Key Takeaways
- Integrating early intervention strategies for HF and T2D can prevent CKD, enhancing patient outcomes and reducing disease progression.
- Standardized protocols and education are crucial for improving early CKD screening across diverse healthcare settings.
Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does a successful CRM prevention or screening program look like in practice?
- Can early intervention in patients with HF or T2D prevent CKD or vice versa?
- How can early screening for CKD be improved and effectively implemented across different healthcare settings?
- What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
- How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
Keynote Address Tackles AI’s Role in Health Care, Eye Care
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
5